Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain

Propofol-induced injection pain is a common and undesirable adverse effect that can lead to patient distress during induction of anesthesia. Nalbuphine, a kappa-opioid receptor agonist and partial mu-opioid receptor antagonist, and lidocaine, a sodium channel blocker, have both been used to reduce this pain, but evidence regarding their comparative effectiveness remains inconsistent.

This randomized clinical trial will be conducted in the Department of Anesthesiology, PGMI / Hayatabad Medical Complex, Peshawar. A total of 92 adult patients with ASA physical status I-II, scheduled for elective general surgery under general anesthesia, will be enrolled and randomized into two equal groups. Group A will receive intravenous nalbuphine at a dose of 0.1 mg/kg, while Group B will receive intravenous lidocaine at a dose of 4.5 mg/kg (maximum 300 mg), administered 60 seconds prior to induction with propofol. Injection pain will be assessed by the inducing anesthesiologist using a four-point pai

Inclusion criteria

• Age 18-60 years

• Either male or female
• ASA physical status I or II
• Scheduled for elective general surgery under general anesthesia using propofol

Exclusion criteria

• Known hypersensitivity to propofol, nalbuphine, or lidocaine

• Emergency surgery
• Use of analgesics prior to surgery
• Pregnant women
• Lactating women